'Tomudex' (raltitrexed) development: Preclinical, phase I and II studies

Anti-Cancer Drugs

Volumn 8, Issue SUPPL. 2, 1997, Pages

  Judson, Ian R ^a  

^a CRC Centre for Cancer Therapeutics   (United Kingdom)

Author keywords

Advanced colorectal cancer; Efficacy; Palliation; Raltitrexed; Safety; Tomudex

Indexed keywords

CYTOTOXIC AGENT; FLUOROURACIL; METHOTREXATE; RALTITREXED;

ADVANCED CANCER; ASTHENIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER DYSFUNCTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; HUMANS; QUINAZOLINES; THIOPHENES;

EID: 0030823833     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708002-00002     Document Type: Conference Paper

References (16)

1. Jackman AL, Jones TR, Calvert AH: Thymidylate synthase inhibitors: experimental and clinical aspects. In Experimental and Clinical Progress in Cancer Chemotherapy. Edited by Muggia FM. Boston: Martinus Nijhoff; 1985:155-210.
2. Zalcberg JR, Cunningham D, Van Cutsem E, et al.: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996, 14:716-721.
3. Jackman AL, Farrugia DC, Gibson W, et al.: ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995, 31A:1277-1285.
4. Jackman AL, Taylor GA, Gibson W, et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991, 51:5579-5586.
5. Jackman AL, Gibson W: Polyglutamation of the thymidylate synthase inhibitor, ZD 1694 (Tomudex) in normal mouse tissues [abstract]. Proc Am Assoc Cancer Res 1995, 36:377.
6. Jackman AL, Gibson W, Brown FT, et al.: The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. In Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. Advances in Experimental Medicine and Biology. Edited by Rustum YM. New York: Plenum Press; 1993, 339:265-276.
7. Kimbell R, Jackman AL, Boyle FT, et al.: The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to different classes of quinazoline analogues. In Chemistry and Biology of Pteridines and Folates. Advances in Experimental Medicines and Biology. Edited by Ayling JE, Nair MG, Baugh CM. New York: Plenum Press; 1993, 338:597-600.
8. Jodrell DI, Newell DR, Gibson W, et al.: The pharmacokinetics of the quinazoline antifolate ICI 1694 in mice and rats. Cancer Chemother Pharmacol 1991, 28:331-338.
9. Clarke SJ, Jackman AL, Judson IR: The history of the development and clinical use of CB3717 and ICI D1694. In Chemistry and Biology of Pteridines and Folates. Advances in Experimental Medicines and Biology. Edited by Ayling JE, Nair MG, Baugh CM. New York: Plenum Press; 1993, 339:277-290.
10. Clarke SJ, Hanwell J, de Boer M, et al.: Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996, 14:1495-1503.
11. Sorensen JM, Jordan E, Grem JL, et al.: Phase I trial of ZD 1694 (Tomudex), a direct inhibitor of thymidylate synthase [abstract 241]. Ann Oncol 1994, 5 (suppl 5):132.
12. Judson IR, Aherne GW, Maughan T, et al.: Pharmacokinetic studies with Tomudex (ZD 1694) [abstract 304]. Ann Oncol 1996, 7 (suppl 1):88.
13. Cunningham D, Zalcberg JR, Rath U, et al.: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996, 7:961-965.
14. Kerr DJ: Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 1997, 8 (suppl 2):S11-S15.
15. Zalcberg J: Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997, 8 (suppl 2):S17-S22.
16. Cunningham D, Zalcberg J, Smith I, et al.: 'Tomudex' (ZD 1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 1996, 7:179-182.